Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
Eli Lilly Uses GLP-1 Strength To Build Genetic And Oncology Portfolio
10.02.2026 00:23
Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics in a deal valued at up to US$2.4b, expanding into in vivo cell and genetic therapies for autoimmune diseases. The company also extended its partnership with Innovent Biologics to advance oncology and immunology drug candidates for global markets. These moves broaden Eli Lilly’s focus beyond obesity treatments toward RNA based therapies and cell engineering for conditions with significant unmet medical need. Eli Lilly, known for its...
Monday's pre-market session: top gainers and losers in the S&P500 index
09.02.2026 13:35
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
Hims & Hers Stock Plunges. Its Weight Loss Drug Strategy Backfired.
09.02.2026 13:12
Heightened regulatory scrutiny could be a major blow for the online drug retailer, which just shelved its plan for a Wegovy copycat.
Eli Lilly Stock Rises. It’s Acquiring This Cell Therapy Company for $2.4 Billion.
09.02.2026 12:34
Eli Lilly shares rose after the Mounjaro maker said it had agreed to acquire biotechnology company Orna Therapeutics for $2.4 billion in cash. The deal value comprises an upfront payment and subsequent payments upon the achievement of clinical development milestones, Lilly said. Orna Therapeutics develops RNA drugs targeting cancers, genetic disorders, and other chronic conditions.
Eli Lilly Pays $350 Million Upfront in China Biotech Collaboration Deal
09.02.2026 12:29
Lilly partners with Innovent on new cancer and immune therapies, with potential milestones reaching $8.5 billion.
Lilly to buy Orna Therapeutics for up to $2.4 billion
09.02.2026 12:09
Feb 9 () - Eli Lilly will acquire therapy developer Orna Therapeutics for up to $2.4 billion in cash, the companies said on Monday.
Lilly to acquire Orna Therapeutics to advance cell therapies
09.02.2026 12:00
Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna.
Novo Nordisk Stock Soars After Hims & Hers Scraps Copycat Weight-Loss Pill
09.02.2026 11:46
Novo Nordisk stock surged after Hims & Hers scrapped plans to sell a copycat version of the drugmaker’s weight-loss pill following pressure from U.S. regulators. Shares in Novo Nordisk jumped more than 7% in Denmark. The stock also trades in the U.S. as an American depositary receipt with the ticker NVO.
Lilly Deepens Longtime Innovent Partnership
09.02.2026 11:42
Cancer and immunology programs take focus
Innovent and Lilly to advance new oncology and immunology medicines
09.02.2026 11:01
Innovent will receive an upfront payment of $350m under the agreement.
Eli Lilly Bets $2.4 Billion On Small Biotech To Boost Future Cell Treatments
09.02.2026 10:11
Eli Lilly shares rise after announcing a $2.4 billion deal to buy Orna Therapeutics, strengthening its push into genetic medicine despite mixed markets.
FDA "Swift Action" Warning Sends Hims & Hers into a Tailspin
09.02.2026 09:30
Hims & Hers is facing intense selling pressure following a direct warning from the FDA targeting the large-scale marketing of compounded weight-loss drugs. This regulatory threat is striking at the heart of the company's newest growth engine, casting a shadow over its business model even as the broader market hits record highs.
Novo Nordisk shares rise as Hims abandons $49 weight-loss pill
09.02.2026 09:13
COPENHAGEN, Feb 9 () - Novo Nordisk's shares jumped more than 8% on Monday after telehealth firm Hims & Hers cancelled the launch of a $49 weight-loss pill over the weekend, following legal threats from Novo and the U. Hims introduced the compounded pill based on semaglutide - a key ingredient in Novo's blockbuster drugs Wegovy and Ozempic - last Thursday, prompting pushback from the Danish drugmaker and regulatory authorities.
Deutsche Bank Maintains Buy on Eli Lilly and Co, Raises Price Target to $1285
09.02.2026 08:48
Deutsche Bank analyst James Shin maintains Eli Lilly and Co (NYSE:LLY) with a Buy and raises the price target from $1200 to $1285.
Eli Lilly Agrees To Acquire Orna Therapeutics For Up To $2.4B
09.02.2026 08:05
Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna.Orna
Innovent Biologics Strikes Partnership Deal With Eli Lilly
09.02.2026 05:57
Chinese drugmaker Innovent Biologics and Eli Lilly plan to target cancer and immune system diseases under the partnership.
Goldman Sachs Reaffirms Buy on Eli Lilly and Company (LLY), Citing 25% Growth Outlook
07.02.2026 13:33
Eli Lilly and Company (NYSE:LLY) is included among 13 Best Long Term Low Risk Stocks to Buy Now. On February 5, Goldman Sachs raised its price recommendation on Eli Lilly and Company (NYSE:LLY) to $1,260 from $1,145. The firm reiterated its Buy rating on the stock. Shares jumped about 10% after the company posted a […]
The Weight-Loss Price Wars Are Breaking Big Pharma’s Business Model
07.02.2026 10:30
Two years ago, a GLP-1 prescription could cost an uninsured patient more than $1,000 a month. In the world of Big Pharma, this is unheard of. Typically, drug prices climb or plateau until generics arrive years later.
Eli Lilly Pricing Deals And Partnerships Reset Outlook For Weight-Loss Drugs
07.02.2026 10:06
Eli Lilly (NYSE:LLY) has agreed to landmark US government drug pricing deals covering key obesity drugs Zepbound and Mounjaro. The agreement includes broader Medicare coverage and access through the new government-run TrumpRx platform at discounted prices. US policy changes are aimed at expanding patient access to obesity treatments and could influence drug pricing across the sector. Eli Lilly has also entered partnerships with Seamless Therapeutics for hearing loss treatments and Repertoire...